Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ABL DiagnosticsFRA:9BK0 50 Current Ratio is 2.41 as of Dec. 2025, which is 85% below its 10-year median of 15.62. GuruFocus rates FRA:9BK0 with a GF Score™ of 50/100 and a GF Value™ of €7.32 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 681 Healthcare Providers & Services companies, ABL Diagnostics ranks better than 72.39% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. ABL Diagnostics's current ratio for the quarter that ended in Dec. 2025 was 2.41.
ABL Diagnostics has a current ratio of 2.41. It generally indicates good short-term financial strength.
The historical rank and industry rank for ABL Diagnostics's Current Ratio or its related term are showing as below:
FRA:9BK0'
s Current Ratio Range Over the Past 10 Years
Min: 2 Med: 15.62 Max: 132.11
Current: 2.41
During the past 13 years, ABL Diagnostics's highest Current Ratio was 132.11. The lowest was 2.00. And the median was 15.62.
FRA:9BK0's Current Ratio is ranked better than 72.39% of 681
companies
in the Healthcare Providers & Services industry
Industry Median: 1.47
vs FRA:9BK0: 2.41
ABL Diagnostics (FRA:9BK0) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
ABL Diagnostics Current Ratio Related Terms
ABL Diagnostics Current Ratio Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:9BK0 vs VEEV, BTSG, TEM: Current Ratio Comparison
For the Health Information Services subindustry, ABL Diagnostics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics Current Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Current Ratio distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics (FRA:9BK0) has a Current Ratio of 2.41 as of Dec. 2025. This is 85% below median its historical median of 15.62. Over the past decade, ABL Diagnostics' Current Ratio has ranged from 2.00 to 132.11. According to the industry distribution chart, ABL Diagnostics ranks #188 out of 681 companies in the Healthcare Providers & Services industry, placing it in the top 27.6%.
Is ABL Diagnostics' Current Ratio too high?
ABL Diagnostics' current Current Ratio of 2.41 is 85% below median its 10-year median of 15.62. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 132.11. The Healthcare Providers & Services industry median Current Ratio is 1.47. ABL Diagnostics' value of 2.41 is 63.9% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #188 out of 681 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, ABL Diagnostics has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' Current Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #188 out of 681 companies for Current Ratio. This puts ABL Diagnostics in the upper half of its industry. The industry median Current Ratio is 1.47. ABL Diagnostics' value of 2.41 is 63.9% above this benchmark. Historically, ABL Diagnostics' own Current Ratio has ranged from 2.00 to 132.11 over the past decade. While the company's 10-year median is 15.62 vs. the industry median of 1.47, ABL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Healthcare Providers & Services company?
The median Current Ratio among Healthcare Providers & Services companies is 1.47, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current Current Ratio of 2.41 is 63.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Current Ratio is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current Current Ratio is 2.41, which is 85% below median its own 10-year median of 15.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (FRA:9BK0) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.32, compared to a current price of €2.76 — trading 62.3% below its estimated fair value. The current Current Ratio is 2.41, which is 85% below median its 10-year median of 15.62 and 63.9% above the Healthcare Providers & Services industry median of 1.47. ABL Diagnostics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For ABL Diagnostics (FRA:9BK0), the current Current Ratio is 2.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (FRA:9BK0) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.76 is trading 62.3% below its estimated GF Value™ of €7.32.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for FRA:9BK0:
Current Ratio: 2.41 (85% below median its 10-year median of 15.62)
GF Value™: €7.32 vs. price of €2.76 (62.3% below fair value)
Industry Position: 63.9% above the Healthcare Providers & Services median (#188 of 681)
No single metric tells the full story. See the FRA:9BK0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
50GF Score
Get the complete analysis for FRA:9BK0
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9BK0 has been successfully added to your 
